top of page



Professor Salim Yusuf (born in India, 1952) is an internationally renowned cardiologist and epidemiologist and distinguished University Professor of Medicine, and Executive Director of the Population Health Research Institute, McMaster University and Chief Scientist, Hamilton Health Sciences. Past President of the World Heart Federation, Prof. Yusuf’s work over 40 years has substantially improved the prevention and treatment of cardiovascular disease, thereby benefitting millions of people. Medically qualified in Bangalore 1976, he received a Rhodes Scholarship and obtained a DPhil from Oxford, during which he (along with Richard Peto and Peter Sleight Rory Collins) initiated the concepts of large, simple trials, and meta-analysis. He coordinated the first ISIS trial which set the structure for future international collaborative work in cardiovascular disease and demonstrated the value of beta-blockers in myocardial infarction.

In 1984, he moved to the National Institutes of Health, Bethesda, USA, where he developed and led the SOLVD trial (establishing the value of ACE-inhibitors in heart failure and LV dysfunction) and DIG trial (clarifying the role of digitalis).

In 1992 he moved to McMaster University, where he established a program of research in cardiovascular diseases and prevention in over 100 countries, culminating in the creation of the Population Health Research Institute, which he founded and heads. The work by his group has lead to a better understanding of risk factors for heart disease and strokes globally, the discovery of new treatments such as ACE inhibitors, dual antiplatelets, and novel antithrombotic agents to reduce mortality, heart attacks, strokes, heart failure and limb ischemia. His current work explores the role of the environment, health policies and health systems in influencing cardiovascular disease mortality globally. By involving researchers in collaborative networks, and by providing practical training in the conduct of important research projects, he has helped to impart a deep understanding of the key principles that underlie epidemiological research in several hundred trainees who have benefited from his direct supervision. Prof. Yusuf holds a Heart and Stroke Foundation of Ontario Research Chair, was a Senior Scientist of the Canadian Institutes of Health Research (1999 – 2004), and has received more than 40 international and national awards for research. He has published more than 1000 articles in refereed journals, rising to the second most cited researcher in the world for 2011.


- Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in

high-risk patients. NEJM. 2000. Time cited: 5,226.

- Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. LANCET. 2004. Times cited: 3,765.

- Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. NEJM. 2001 Times Cited: 3,535.


- Lifetime Research Achievement award of the Canadian Cardiovascular Society;

- Paul Wood Silver Medal of the British Cardiac Society;

- European Society of Cardiology gold medal;

- Royal Society of Canada Inductee;

- Canadian Medical Hall of Fame Inductee;

- Officer of the Order of Canada;

- Gairdner Wightman Award in 2014;

- Prix Galien Research Award;

- Louis and Artur Lucian Award for Research;

- Clinical Research Award of the American Heart Association.

bottom of page